[Clinical Efficacy of Second-generation Tyrosine Kinase Inhibitor in Treating Chronic Myeloid Leukemia].

Objective: To evaluate the efficacy of second-generation tyrosine kinase inhibitor (TKI) in treating chronic myeloid leukemia (CML).

Methods: A total of 97 patients with CML were enrolled. The patients were treated with TKI and monitored with complete blood count, cytogenetic and molecular indicators during the course of therapy.

[Efficacy of tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients].

Objective: To evaluate the effects of tyrosine kinase inhibitors (TKI) in the treatment of chronic myeloid leukemia.

Methods: There were total 655 cases of chronic myeloid leukemia treated in one single-institution enrolled in this study. The dosage of TKI Imatinib was 400 mg/d for chronic phase, 600 mg/d for accelerated and blast phase respectively.

[A paired case-control study for assessing the relationship between the incidence of malignant lymphomas and the viruses infections].

Objective: To evaluate the relationships between the viruses infections and the incidence of malignant lymphomas (ML) in Sichuan province.

Methods: A hospital-based paired case-control study was designed with two controls per case. The case group comprised 97 cases diagnosed as ML by pathological examination; the control group A consisted of 194 subjects randomly selected from those with non-malignancies by matching on both gender and age in the corresponding period.

[A case-control study for assessing the relation between the incidence of malignant lymphomas and environmental factors in Sichuan province].

Objective: To evaluate the relationships of malignant lymphoma (ML) and exposure factors, including environmental, drug using, socioeconomic level and life style etc.

Methods: (1) Hospital-based case-control study with 1:2 matching was used; (2) 150 cases of ML and 300 controls were resulted; (3) logistic regression was used.

Results: (1) Adjust odds ratios (aOR) regarding contact to organic solvents were: benzene aOR = 2.